.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,844,013

« Back to Dashboard
Patent 6,844,013 protects PICATO and is included in one NDA. There has been one Paragraph IV challenge on Picato.

This patent has eighteen patent family members in fifteen countries.

Summary for Patent: 6,844,013

Title: Methods of stimulating the immune system
Abstract:This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
Inventor(s): Aylward; James Harrison (St. Lucia, AU)
Assignee: Peplin Research Pty Ltd (Fortitude Valley, AT)
Application Number:09/888,997
Patent Claim Types:
see list of patent claims
Use; Process; Composition;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 24th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Leo Pharma As
PICATO
ingenol mebutate
GEL;TOPICAL202833-001Jan 23, 2012RXYes6,844,013► subscribe TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION
Leo Pharma As
PICATO
ingenol mebutate
GEL;TOPICAL202833-002Jan 23, 2012RXYes6,844,013► subscribe TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,844,013

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPO 8640Aug 19, 1997

Non-Orange Book Patents for Patent: 6,844,013

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,410,656Anti-cancer compounds► subscribe
6,432,452 Anti-cancer compounds► subscribe
6,787,161 Anti-cancer compounds► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,844,013

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria397580► subscribe
Australia736230► subscribe
Australia8721798► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc